[go: up one dir, main page]

WO2001066689A3 - Nouveaux acides nucleiques et polypeptides - Google Patents

Nouveaux acides nucleiques et polypeptides Download PDF

Info

Publication number
WO2001066689A3
WO2001066689A3 PCT/US2001/004942 US0104942W WO0166689A3 WO 2001066689 A3 WO2001066689 A3 WO 2001066689A3 US 0104942 W US0104942 W US 0104942W WO 0166689 A3 WO0166689 A3 WO 0166689A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
polypeptides
novel nucleic
novel
present
Prior art date
Application number
PCT/US2001/004942
Other languages
English (en)
Other versions
WO2001066689A2 (fr
Inventor
Y Tom Tang
Chenghua Liu
Vinod Asundi
Chongjun Xu
Tom Wehrman
Feiyan Ren
Yunqing Ma
Ping Zhou
Qing A Zhao
Yonghong Yang
Radoje T Drmanac
Jie Zhang
Rui-Hong Chen
Aidong J Xue
Jian-Rui Wang
Original Assignee
Hyseq Inc
Y Tom Tang
Chenghua Liu
Vinod Asundi
Chongjun Xu
Tom Wehrman
Feiyan Ren
Yunqing Ma
Ping Zhou
Qing A Zhao
Yonghong Yang
Radoje T Drmanac
Jie Zhang
Chen Rui Hong
Aidong J Xue
Wang Jian Rui
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyseq Inc, Y Tom Tang, Chenghua Liu, Vinod Asundi, Chongjun Xu, Tom Wehrman, Feiyan Ren, Yunqing Ma, Ping Zhou, Qing A Zhao, Yonghong Yang, Radoje T Drmanac, Jie Zhang, Chen Rui Hong, Aidong J Xue, Wang Jian Rui filed Critical Hyseq Inc
Priority to AU2001245280A priority Critical patent/AU2001245280A1/en
Priority to US10/221,278 priority patent/US20040034208A1/en
Priority to CA002402293A priority patent/CA2402293A1/fr
Priority to EP01918174A priority patent/EP1261743A2/fr
Publication of WO2001066689A2 publication Critical patent/WO2001066689A2/fr
Publication of WO2001066689A3 publication Critical patent/WO2001066689A3/fr
Priority to US10/291,172 priority patent/US20030228584A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention se rapporte à de nouveaux acides nucléiques, à de nouvelles séquences de polypeptides codées par ces acides nucléiques et à des utilisations de ceux-ci.
PCT/US2001/004942 2000-03-07 2001-03-05 Nouveaux acides nucleiques et polypeptides WO2001066689A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2001245280A AU2001245280A1 (en) 2000-03-07 2001-03-05 Novel nucleic acids and polypeptides
US10/221,278 US20040034208A1 (en) 2001-03-05 2001-03-05 Novel nucleic acids and polypeptides
CA002402293A CA2402293A1 (fr) 2000-03-07 2001-03-05 Nouveaux acides nucleiques et polypeptides
EP01918174A EP1261743A2 (fr) 2000-03-07 2001-03-05 Nouveaux acides nucleiques et polypeptides
US10/291,172 US20030228584A1 (en) 2000-03-07 2002-11-08 Novel nucleic acids and polypeptides

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US51970500A 2000-03-07 2000-03-07
US09/519,705 2000-03-07
US57445400A 2000-05-19 2000-05-19
US09/574,454 2000-05-19
US59619300A 2000-06-17 2000-06-17
US09/596,193 2000-06-17
US61684700A 2000-07-14 2000-07-14
US09/616,847 2000-07-14
US66536300A 2000-09-19 2000-09-19
US09/665,363 2000-09-19
US69326700A 2000-10-20 2000-10-20
US09/693,267 2000-10-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/291,172 Continuation-In-Part US20030228584A1 (en) 2000-03-07 2002-11-08 Novel nucleic acids and polypeptides

Publications (2)

Publication Number Publication Date
WO2001066689A2 WO2001066689A2 (fr) 2001-09-13
WO2001066689A3 true WO2001066689A3 (fr) 2002-05-30

Family

ID=27560092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/004942 WO2001066689A2 (fr) 2000-03-07 2001-03-05 Nouveaux acides nucleiques et polypeptides

Country Status (4)

Country Link
EP (1) EP1261743A2 (fr)
AU (1) AU2001245280A1 (fr)
CA (1) CA2402293A1 (fr)
WO (1) WO2001066689A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
US7425612B2 (en) 2002-06-06 2008-09-16 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
WO2024138128A2 (fr) 2022-12-23 2024-06-27 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953682B2 (en) 2000-02-10 2005-10-11 Millennium Pharmaceuticals, Inc. Nucleic acid sequences encoding adenylate kinase, phospholipid scramblase-like, DNA fragmentation factor-like, phosphatidylserine synthase-like, and atpase-like molecules and uses therefor
US20040082051A1 (en) * 2000-12-14 2004-04-29 Zhimin Zhu Regulation of human uridine kinase
US20040072997A1 (en) * 2000-12-20 2004-04-15 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2002250143A1 (en) * 2001-03-16 2002-10-03 Eli Lilly And Company Lp mammalian proteins; related reagents
DE60238143D1 (de) 2001-09-18 2010-12-09 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
AU2003226444A1 (en) * 2002-04-01 2003-10-13 Asahi Kasei Pharma Corporation Vascularization controlling gene
EP1565488A4 (fr) * 2002-05-15 2007-10-03 Avalon Pharmaceuticals Gene lie au cancer servant de cible pour la chimiotherapie
GB0215295D0 (en) * 2002-07-02 2002-08-14 Inpharmatica Ltd Proteins
US20070036810A1 (en) * 2003-03-26 2007-02-15 Vadim Iourgenko Cyclic amp response element activator proteins and uses related thereto
US7361747B2 (en) * 2003-05-22 2008-04-22 The University Of Hong Kong Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus
GB0320878D0 (en) * 2003-09-05 2003-10-08 Celltech R&D Ltd A protein involved in carcinoma
EP2083089A1 (fr) 2003-10-23 2009-07-29 Illumigen Biosciences, Inc. Détection de mutations dans un gène associées à la résistance à l'infection virale, oas1
EP3858387A1 (fr) 2003-11-06 2021-08-04 Seagen Inc. Composés de monométhylvaline capables de conjugaison aux ligands
RU2404810C9 (ru) 2004-06-01 2015-06-20 Дженентек, Инк. Конъюгаты антитело-лекарственное средство и способы
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006034488A2 (fr) 2004-09-23 2006-03-30 Genentech, Inc. Anticorps et conjugués produits avec de la cystéine
WO2006097335A1 (fr) * 2005-03-18 2006-09-21 Universität Zürich Nouvel element de la voie de signalisation wg/wnt
UA95446C2 (ru) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1
CA2621363C (fr) 2005-09-13 2015-07-07 National Research Council Of Canada Methodes et compositions permettant de moduler l'activite des cellules tumorales
US8575107B2 (en) * 2008-01-22 2013-11-05 Compugen Ltd. Clusterin derived peptide
JP2013504585A (ja) 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体
ES2734886T3 (es) 2009-11-24 2019-12-12 Alethia Biotherapeutics Inc Anticuerpos anti-clusterina y fragmentos de unión a antígeno y su uso para reducir el volumen tumoral
EP2662095A1 (fr) 2010-04-15 2013-11-13 Spirogen Sàrl Pyrrolobenzodiazépines et conjugués de celles-ci
JP2013534520A (ja) 2010-06-08 2013-09-05 ジェネンテック， インコーポレイテッド システイン操作抗体及びコンジュゲート
US20120121595A1 (en) * 2010-10-11 2012-05-17 University Of Southern California FRAGMENT OF SECRETED HEAT SHOCK PROTEIN-90ALPHA (Hsp90ALPHA) AS VACCINES OR EPITOPE FOR MONOCLONAL ANTIBODY DRUGS OR TARGET FOR SMALL MOLECULE DRUGS AGAINST A RANGE OF SOLID HUMAN TUMORS
WO2012074757A1 (fr) 2010-11-17 2012-06-07 Genentech, Inc. Conjugués d'anticorps alaninyl-maytansinol
CN103608684B (zh) 2011-05-12 2016-05-04 基因泰克公司 利用框架签名肽检测动物样品中的治疗性抗体的多重反应监测lc-ms/ms方法
HUE025661T2 (en) 2011-10-14 2016-04-28 Medimmune Ltd Pyrrolobenzodiazepines and their conjugates
NZ626742A (en) 2012-02-22 2016-06-24 Alethia Biotherapeutics Inc Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
TR201808051T4 (tr) 2012-10-12 2018-06-21 Adc Therapeutics Sa Pirrolobenzodiazepin antikor konjugatları.
PT2766048E (pt) 2012-10-12 2015-02-25 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
DK2906251T3 (da) 2012-10-12 2017-11-20 Adc Therapeutics Sa Pyrrolobenzodiazepin-anti-CD22-antistofkonjugater
SMT201900017T1 (it) 2012-10-12 2019-02-28 Medimmune Ltd Coniugati pirrolobenzodiazepina-anticorpo
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
DK2906253T3 (en) 2012-10-12 2018-10-22 Adc Therapeutics Sa Pyrrolobenzodiazepine anti-PSMA antibody conjugates
WO2014057114A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués pyrrolobenzodiazepine-anticorps anti-psma
CN105307685B (zh) 2013-03-13 2019-03-08 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
ES2731779T3 (es) 2013-03-13 2019-11-19 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
CA2905181C (fr) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines et ses conjugues servant a fournir une therapie ciblee
WO2015023355A1 (fr) 2013-08-12 2015-02-19 Genentech, Inc. Conjugués anticorps-médicament dimérique 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
WO2015052534A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
BR112016012410A2 (pt) 2013-12-16 2017-09-26 Genentech Inc conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica
WO2015095227A2 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
CA2929565A1 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composes conjugues anticorps-medicament dimerique a base de 1-(chloromethyl)-2,3-dihydro-1 h-benzo [e]indole, et methodes d'utilisation et de traitement
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN106714844B (zh) 2014-09-12 2022-08-05 基因泰克公司 蒽环类二硫化物中间体、抗体-药物缀合物和方法
BR112017003236A2 (pt) 2014-09-12 2017-11-28 Genentech Inc anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica
EA201790359A1 (ru) 2014-09-17 2017-08-31 Дженентек Инк. Пирролобензодиазепины и их конъюгаты, связанные дисульфидной связью с антителами
BR112017011111A2 (pt) 2014-11-25 2017-12-26 Adc Therapeutics Sa conjugados de pirrolobenzodiazepina-anticorpo
KR20170086121A (ko) 2014-12-03 2017-07-25 제넨테크, 인크. 4급 아민 화합물 및 그의 항체-약물 접합체
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
WO2017201449A1 (fr) 2016-05-20 2017-11-23 Genentech, Inc. Conjugués anticorps-protac et procédés d'utilisation
JP7022080B2 (ja) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
CN109476648B (zh) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 司维司群抗体-药物缀合物和使用方法
EP3496763A1 (fr) 2016-08-11 2019-06-19 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
DK3544636T3 (da) 2017-02-08 2021-05-10 Adc Therapeutics Sa Pyrrolobenzodiazepin-antistof-konjugater
WO2018157773A1 (fr) * 2017-02-28 2018-09-07 暨南大学 Peptide de réparation destiné à être utilisé pour favoriser la réparation et la régénération tissulaires post-traumatiques, et son application
SI3612537T1 (sl) 2017-04-18 2022-10-28 Medimmune Limited Konjugati pirolobenzodiazepina
US20200129637A1 (en) 2017-04-20 2020-04-30 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
WO2018229222A1 (fr) 2017-06-14 2018-12-20 Adc Therapeutics Sa Régimes posologiques pour l'administration d'un cam anti-cd19
FR3069156B1 (fr) * 2017-07-21 2019-08-09 Universite de Bordeaux Clusterine pour son utilisation dans le traitement des micro-angiopathies thrombotiques
KR102270107B1 (ko) 2017-08-18 2021-06-30 메디뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
SG11202001907QA (en) 2017-09-20 2020-04-29 Ph Pharma Co Ltd Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP7708662B2 (ja) 2018-10-24 2025-07-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法
CN113227119A (zh) 2018-12-10 2021-08-06 基因泰克公司 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
ES2967878T3 (es) 2019-03-15 2024-05-06 Medimmune Ltd Dímeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento del cáncer
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
EP4426727A2 (fr) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Conjugaison spécifique d'un anticorps
WO2024220546A2 (fr) 2023-04-17 2024-10-24 Peak Bio, Inc. Anticorps et conjugués anticorps-médicament et procédés d'utilisation, processus synthétiques et intermédiaires

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 6 February 1997 (1997-02-06), WANG ET AL.: "Direct submission", XP002908399, Database accession no. U51114 *
WATSON ET AL.: "The science used in recombinant DNA industry. Recombinant DNA; A short course", 1983, W.H. FREEMAN AND COMPANY, NEW YORK, XP002945246 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7425612B2 (en) 2002-06-06 2008-09-16 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
US7705141B2 (en) 2002-06-06 2010-04-27 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
US7847065B2 (en) 2002-06-06 2010-12-07 Oncotherapy Science, Inc. CXADRL1 polypeptides relating to human cancers
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
WO2024138128A2 (fr) 2022-12-23 2024-06-27 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations

Also Published As

Publication number Publication date
EP1261743A2 (fr) 2002-12-04
AU2001245280A1 (en) 2001-09-17
WO2001066689A2 (fr) 2001-09-13
CA2402293A1 (fr) 2001-09-13

Similar Documents

Publication Publication Date Title
WO2001075067A8 (fr) Nouveaux acides nucleiques et polypeptides
WO2001057188A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001057190A3 (fr) Acides nucleiques et polypeptides
WO2002022660A3 (fr) Noveaux acides nucleiques et polypeptides
WO2001066689A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002031111A3 (fr) Acides nucleiques et polypeptides
WO2001088088A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002059260A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2003054152A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2003025148A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002070539A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2003023013A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002081731A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001053312A8 (fr) Nouveaux acides nucleiques et polypeptides
WO2001053455A3 (fr) Nouveaux acides nucleiques et polypeptides associes
WO2004009834A3 (fr) Nouveaux acides nucleiques et polypeptides secretes
WO2004080148A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2003029271A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001079449A3 (fr) Acides nucleiques et polypeptides nouveaux
WO2002018424A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2004087874A3 (fr) Acides nucleiques et polypeptides
WO2003080795A8 (fr) Nouveaux acides nucléiques et polypeptides sécrétés
WO2001002571A3 (fr) Nouvel antagoniste du recepteur d'interleukin-1 et ses utilisations
WO2005049806A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001075068A3 (fr) Proteines secretee et polynucleotides codant pour ces proteines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2402293

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001918174

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10291172

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001918174

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10221278

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001918174

Country of ref document: EP